Clinical Trials

A Phase 1 clinical trial is currently recruiting patients with hepatocellular carcinoma to evaluate Cy7-based fluorophores for near-infrared-II (NIR-II) fluorescence image-guided surgery. Academically sponsored by the Institute of Automation, Chinese Academy of Sciences, the study assesses the precision and feasibility of targeting integrin alpha-6 (ITGA6) for real-time fluorescence-guided tumor resection. This research underscores the emerging translational utility of Cy7 conjugates as intraoperative imaging reagents in surgical oncology.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06204835 RECRUITING
Hepatocellular Carcinoma
Institute of Automation, Chinese Academy of Sciences
2024-01-07 PHASE1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Cy7 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Cy7 (Sulfo-Cyanine7) covalently conjugates to targeted biological molecules such as antibodies and peptides, generating near-infrared fluorescence upon excitation while preserving native binding affinity and molecular stability. This specific fluorescent reporter emission enables precise optical detection of tagged cellular receptors, providing real-time tumor visualization and margin identification during image-guided surgical intervention for hepatocellular carcinoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.